{
    "patient": {
        "Name": "Megan Nguyen",
        "DateOfBirth": "1984-04-09",
        "Sex": "Female",
        "Diagnosis": "Squamous cell carcinoma",
        "BodyPart": "Skin",
        "Physician": "Dr. Joshua Navarro",
        "TreatingInstitution": "Delgado Ltd"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Skin",
            "CollectedDate": "2023-08-01",
            "ReceivedDate": "2023-08-06",
            "TumorPercentage": "53%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-08-04",
            "ReceivedDate": "2023-08-07"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "CDKN2A",
                "DNA Alteration": "c.89C>T",
                "GeneMutation": "p.V51D Frameshift-LOF",
                "VariantAlleleFraction": "3.48%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "FGFR2",
                "DNA Alteration": "c.1124A>G",
                "GeneMutation": "p.V679F Spliceregionvariant-LOF",
                "VariantAlleleFraction": "11.12%"
            },
            {
                "Gene": "CALR",
                "DNA Alteration": "c.1092_1143del52",
                "GeneMutation": "p.N549K Frameshift-LOF",
                "VariantAlleleFraction": "16.65%"
            },
            {
                "Gene": "U2AF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.Q157X Spliceregionvariant-LOF",
                "VariantAlleleFraction": "22.15%"
            },
            {
                "Gene": "STAT5B",
                "DNA Alteration": "c.1924A>C",
                "GeneMutation": "p.K659E Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "5.23%"
            },
            {
                "Gene": "EGFR",
                "DNA Alteration": "c.2375T>A",
                "GeneMutation": "p.L718X Frameshift-LOF",
                "VariantAlleleFraction": "12.69%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "PTPN11",
            "FGFR3",
            "ARID2",
            "MET"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "48 m/Mb",
            "Tmbpercentile": "96%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Stable"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.V49M Spliceregionvariant-LOF",
                "VariantAlleleFraction": "3.55%"
            },
            {
                "Gene": "APC",
                "DNA Alteration": "c.3920T>A",
                "GeneMutation": "p.I1307K Spliceregionvariant-LOF",
                "VariantAlleleFraction": "6.03%"
            },
            {
                "Gene": "KRAS",
                "DNA Alteration": "c.38G>C",
                "GeneMutation": "p.Q61H Stopgain-LOF",
                "VariantAlleleFraction": "2.78%"
            },
            {
                "Gene": "MAPK1",
                "DNA Alteration": "c.964G>A",
                "GeneMutation": "p.E322K Stopgain-LOF",
                "VariantAlleleFraction": "1.87%"
            },
            {
                "Gene": "BLM",
                "DNA Alteration": "c.2207_2212delinsTAGATTC",
                "GeneMutation": "p.Y736fs*4 Nonsense-LOF",
                "VariantAlleleFraction": "8.75%"
            },
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.V49M Nonsense-GOF",
                "VariantAlleleFraction": "9.39%"
            },
            {
                "Gene": "NCSTN",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A572G Spliceregionvariant-GOF",
                "VariantAlleleFraction": "7.86%"
            },
            {
                "Gene": "FBXW7",
                "DNA Alteration": "c.1394G>A",
                "GeneMutation": "p.R465H Nonsense-GOF",
                "VariantAlleleFraction": "5.07%"
            },
            {
                "Gene": "HBB",
                "DNA Alteration": "c.20A>T",
                "GeneMutation": "p.E7V Frameshift-LOF",
                "VariantAlleleFraction": "2.41%"
            },
            {
                "Gene": "ZEB2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.H1038R Nonsense-GOF",
                "VariantAlleleFraction": "3.73%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "DPYD",
        "HDAC1",
        "BRAF"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "CDKN2A",
                "DNA Alteration": "c.89C>T",
                "GeneMutation": "p.V51D Frameshift-LOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "3.48%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "FGFR2",
                "DNA Alteration": "c.1124A>G",
                "GeneMutation": "p.V679F Spliceregionvariant-LOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "11.12%"
            },
            {
                "Gene": "CALR",
                "DNA Alteration": "c.1092_1143del52",
                "GeneMutation": "p.N549K Frameshift-LOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "16.65%"
            },
            {
                "Gene": "U2AF1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.Q157X Spliceregionvariant-LOF",
                "description": "TP53 encodes a protein that is a transcription factor that regulates the expression of genes involved in cell cycle arrest, apoptosis, and DNA repair. TP53 is a tumor suppressor gene that is mutated in many cancers. Mutations in TP53 are associated with cancer progression.",
                "VariantAlleleFraction": "22.15%"
            },
            {
                "Gene": "STAT5B",
                "DNA Alteration": "c.1924A>C",
                "GeneMutation": "p.K659E Missensevariant(exon2)-GOF",
                "description": "NFE2L2 acts as a transcription factor for proteins that contain an antioxidant response element (ARE) within their promoter sequence. Genes that contain ARE are involved in injury and inflammation response. Activating mutations and overexpression of NFE2L2 are associated with cancer progression.",
                "VariantAlleleFraction": "5.23%"
            },
            {
                "Gene": "EGFR",
                "DNA Alteration": "c.2375T>A",
                "GeneMutation": "p.L718X Frameshift-LOF",
                "description": "PTEN encodes a phosphatase that acts as a tumor suppressor by negatively regulating the PI3K-AKT-mTOR pathway. Loss of function mutations, copy number loss, and underexpression of PTEN are associated with cancer progression.",
                "VariantAlleleFraction": "12.69%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-07-31"
    },
    "other": {
        "ReportId": "3863",
        "ReportDate": "2023-08-05",
        "SignedBy": "Joshua Navarro",
        "Supervisor": "Dr. Steven Stone"
    }
}